An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma

Targeted therapies have introduced a paradigm shift in the management of metastatic renal cell carcinoma. Currently, four molecules (sunitinib, pazopanib, bevacizumab plus interferon, temsirolimus) are considered in first-line therapy, and three other molecules for second, or subsequent lines of the...

Full description

Saved in:
Bibliographic Details
Main Authors: Sun, Maxine, Shariat, Shahrokh F., Trinh, Quoc-Dien, Meskawi, Malek, Bianchi, Marco, Hansen, Jens, Abdollah, Firas, Perrotte, Paul, Karakiewicz, Pierre I.
Format: Artigo
Language:Inglês
Published: SAGE Publications 2013
Subjects:
Reviews
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3607488/
https://ncbi.nlm.nih.gov/pubmed/23554847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287212466128
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items